1709-14-4

Basic information

• Product Name: 3,3-dichloroazepan-2-one
• Synonyms: 2H-azepin-2-one, 3,3-dichlorohexahydro-
• CAS NO: 1709-14-4
• Molecular Formula: C₆H₉Cl₂NO
• Molecular Weight: 182.0478
• Mol File: 1709-14-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 327.3°C at 760 mmHg
• Flash Point: 151.8°C
• Density: 1.32g/cm³
• Vapor Pressure: 0.000203mmHg at 25°C
• Refractive Index: 1.51
• CAS DataBase Reference: 3,3-dichloroazepan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3-dichloroazepan-2-one(1709-14-4)
• EPA Substance Registry System: 3,3-dichloroazepan-2-one(1709-14-4)

Safety Data

• Hazardous Substances Data: 1709-14-4(Hazardous Substances Data)

Usage

General Description

3,3-dichloroazepan-2-one is a chemical compound with the molecular formula C6H10Cl2N2O, signifying the presence of carbon, hydrogen, chlorine, nitrogen, and oxygen atoms in its structure. It belongs to the class of organic compounds known as azepanes, which are saturated polymers containing azepane, a seven member ring that includes one nitrogen atom and six carbon atoms. With its systematic name as 2-azepanone, 3,3-dichloro-, this compound plays a significant utility in the field of chemical research and synthesis. Its properties, as well as potential applications, may largely depend on the functional groups it features.

Upstream product

• 105-60-2 caprolactam 
• 56-23-5 tetrachloromethane 
• 10026-13-8 phosphorus pentachloride 
• 7732-18-5 water 
• 100-64-1 cyclohexanone-oxime 

Downstream Products

• 1468-55-9 3-chloro-hexahydro-azepin-2-one 

Relevant articles and documents

New calcium antagonists: Synthesis, X-ray analysis, and smooth muscle relaxing effect of 3-[O-(benzyl-substituted)-oximino-ethers]-hexahydroazepin-2,3-diones

A series of new Z and E 3-[O-(benzyl-substituted)-oximino-ether]-hexahydroazepin-2,3-diones was prepared from the corresponding hexahydroazepin-2,3-diones and examined as smooth muscle relaxants. E and Z structures were assigned by NMR analysis and confirmed for 16 (E and Z) by an X-ray diffraction using synchrotron radiations. The nitrobenzyl derivative 16 was the most potent in vitro as relaxant of rat trachea precontracted with acetylcholine. The E isomer 16b was more potent than the Z isomer 16a. E isomer 16b is more potent than aminophylline to relax both rat trachea and human bronchus.This derivative acts mainly by inhibiting cellular infux of extracellular calcium since it inhibits potently and dose-dependently the contractions of rat trachea to high concentrations of KCl and to CaCl2 in a depolarizing medium. It appears to act weakly by inducing cGMP and cAMP synthesis. Moreover, its relaxing activity is not related to an inhibition of phosphodiesterases, to opening of potassium channels or to induction of prostaglandin synthesis. Therefore, 16b appears to work mainly as a potent calcium antagonist. (C) 1999 Elsevier Science Ltd.

Radiosensitization of human pancreatic cancer by piperlongumine analogues

Radiotherapy is commonly used to treat advanced pancreatic cancers and can improve survival by 2 months in combination with gemcitabine. However, prognosis and survival improvement remain unsatisfactory, and effective therapies are urgently needed. Piperlongumine has been demonstrated to have therapeutic potentials against various cancers. In this study, we synthesized a series of piperlongumine derivatives and provided evidence that piperlongumine derivatives could be used as effective radiosensitizers in pancreatic cancer. Two compounds enhanced the radiosensitivity of Panc-1 and SW1990 cells. In a pancreatic bi-flank xenograft tumor model, they significantly inhibited tumor growth. Piperlongumine derivatives could induce reactive oxygen species (ROS) expression and regulate the Keap1-Nrf2 protective pathway with enhancement of radiation-induced DNA damage, G2/M-phase cell cycle arrest, and apoptosis. Collectively, our data offer a proof of concept for the use of piperlongumine derivatives as a novel class of radiosensitizers for the treatment of pancreatic cancer.

Piper longum amide analogue containing seven-membered lactam ring and preparation method and application thereof

The invention relates to the technical field of medicine, in particular to a substitutive piper longum amide analogue. The substitutive piper longum amide analogue comprises cis-trans-isomers thereof and any mixture in the form of cis-trans-isomers or pharmaceutical salt of the analogue. The structure of the substitutive piper longum amide analogue is shown in the formula (I). The invention further provides a preparation method of the substitutive piper longum amide compound and application of the substitutive piper longum amide compound to preparation of antitumor drugs.